- A pooled analysis of LEA and CALGB 40503 trials finds that adding bevacizumab to endocrine therapy (ET) extends PFS at the expense of greater toxicity in metastatic hormone receptor (HR)-positive breast cancer.
- PFS benefit did not translate to OS advantage.
Why this matters
- LEA and CALGB 40503, when analyzed individually, had conflicting results.
- Pooled analysis of 2 phase 3 trials of ET with or without bevacizumab (15 mg/kg body weight every 3 weeks).
- Funding: Genentech; Roche; NIH; others.
- Median follow-up, 34 months.
- Bevacizumab+ET (vs ET) resulted in longer PFS (19 vs 14.3 months; unadjusted HR, 0.77; P=.0016).
- Subgroup analysis found greater effect in endocrine-sensitive patients (HR, 0.68; P=.0042).
- Bevacizumab +ET (vs ET) showed superior:
- Objective response rate, 61% vs 40% (P<.01>
- Clinical benefit rate, 77% vs 64% (P=.01).
- No availability of CDK 4/6 inhibitors at the time the studies were performed.